Levels of long-acting anti-HIV bNAb high in infants after 1 or 2 doses – but not high enough
14 October 2020. Related: Conference reports, Paediatric care, PK and drug interactions, HIV prevention and transmission.
Conference reports
23rd International AIDS Conference (AIDS 2020): second reports
28 August 2020. Related: Conference reports.
Capsid inhibitor lenacapavir (GS-6207) allows for 6-monthly dosing
28 August 2020. Related: Conference reports, Antiretrovirals.
Weight gain with integrase inhibitors and TAF: three reports from AIDS 2020
28 August 2020. Related: Conference reports, Side effects.
Dolutegravir non-inferior to efavirenz at week 96 in the NAMSAL study but associated with substantial weight gain
28 August 2020. Related: Conference reports, Treatment strategies.
Switching from efavirenz- to dolutegravir-based ART second-line achieved good rates of suppression: first results from the VISEND study
28 August 2020. Related: Conference reports, Treatment strategies.
Paediatric dolutegravir dosing at AIDS 2020
28 August 2020. Related: Conference reports, Paediatric care.
COVID-19 outcomes in HIV positive people in two large US cohorts
28 August 2020. Related: Conference reports, COVID-19: HIV and COVID-19 coinfection, COVID-19.
AIDS 2020: virtual content now available free and on-demand
28 August 2020. Related: Conference reports, Other news.
Pathways to an HIV cure: online presentations
28 August 2020. Related: Conference reports, Cure-related research.
IAS COVID-19 Conference: introduction
22 July 2020. Related: Conference reports.
Conference opening and making sense of the science
22 July 2020. Related: Conference reports, COVID-19.
HepC drugs for COVID-19: sofosbuvir/daclatasvir show faster recovery and reduced mortality
22 July 2020. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Predictors of response to remdesivir in GS-5773 COVID-19 study
22 July 2020. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
AIDS 2020 online: introduction
22 July 2020. Related: Conference reports.
AIDS 2020: Navigating the website
22 July 2020. Related: Conference reports.
Neural tube defects in two of 1000 conception exposures with dolutegravir: reassuring update from Tsepamo study
22 July 2020. Related: Conference reports, Pregnancy.
Dolutegravir associated with weight gain in African ART programmes: findings from AFRICOS
22 July 2020. Related: Conference reports, Side effects.
ADVANCE 96-week results: dolutegravir weight gain continues, especially in women and when used with TAF – no evidence of a plateau
22 July 2020. Related: Conference reports, Antiretrovirals.
Obesity linked to dolutegravir, especially with TAF, could increase risk of adverse pregnancy outcomes
22 July 2020. Related: Conference reports, Women's health, Pregnancy, Side effects.
Pregnancy meta-analysis: dolutegravir- versus efavirenz-based ART
22 July 2020. Related: Conference reports, Pregnancy.
Long-acting cabotegravir injections are effective as HIV PrEP in gay men and transgender women: results from HPTN 083
22 July 2020. Related: Conference reports, HIV prevention and transmission.
Case report of short-term HIV remission from adding oral nicotinamide to intensified ART
22 July 2020. Related: Conference reports, Cure-related research.
New HIV remission case report at AIDS 2020: full report
22 July 2020. Related: Conference reports, Cure-related research.
23rd International AIDS Conference (AIDS 2020)
26 June 2020. Related: Conference reports.
Conference on Retroviruses and Opportunistic Infections (CROI 2020)
17 April 2020. Related: Conference reports.
Predicted diabetes risk with first-line ART regimens: results from the ADVANCE trial
17 April 2020. Related: Conference reports, Side effects.
Dolutegravir-based ART is safe and effective for pregnant women: first results from the VESTED trial
17 April 2020. Related: Conference reports, Pregnancy.
A step forward for AAV-mediated delivery of bNAbs
17 April 2020. Related: Conference reports, Cure-related research, Basic science and immunology.
10th International Workshop of HIV & Women
17 April 2020. Related: Conference reports.
No neural tube defects among pregnancies with periconception dolutegravir exposure in the Dolomite-EPPICC cohort study
17 April 2020. Related: Conference reports.
Conference on Retroviruses and Opportunistic Infections (CROI 2020)
12 March 2020. Related: Conference reports.
CROI 2020: Special session on COVID-19
12 March 2020. Related: Conference reports, Virology, COVID-19: pathogenesis, COVID-19: on the web.
Monthly islatravir for PEP and PrEP: 12 pills a year could cover unmet need for HIV prevention in billions of people globally
12 March 2020. Related: Conference reports, HIV prevention and transmission.
Long-acting cabotegravir and rilpivirine injections support two-monthly dosing
12 March 2020. Related: Conference reports, Antiretrovirals.
Safety and PK of bNAb elipovimab (GS-9722) support two-weekly dosing
12 March 2020. Related: Conference reports, Antiretrovirals.
First results with long-acting capsid inhibitor GS-6207: oral and subcutaneous formulations for use in naïve and multidrug resistance
12 March 2020. Related: Conference reports, Antiretrovirals.
Predicted diabetes risk with first-line ART regimens: results from the ADVANCE trial
12 March 2020. Related: Conference reports, Side effects.
Postpartum weight gain is higher with dolutegravir- compared with efavirenz-based ART among African women
12 March 2020. Related: Conference reports, Pregnancy, Side effects.
London patient is second person to be cured of HIV from allogeneic stem-cell transplant
12 March 2020. Related: Conference reports, Cure-related research.
The London Patient tells his story as second person cured of HIV
12 March 2020. Related: Conference reports, Cure-related research.
17th European AIDS Conference (EACS 2019)
24 February 2020. Related: Conference reports.
Long-acting cabotegravir and rilpivirine: similar results in women and men
24 February 2020. Related: Conference reports, Antiretrovirals, Women's health.
Antiretroviral pregnancy registry: dolutegravir update
24 February 2020. Related: Conference reports, Pregnancy.
Bictegravir/emtricitabine/tenofovir alafenamide appears to be safe and effective in women: results from a pooled analysis
24 February 2020. Related: Conference reports, Pregnancy.
No HIV transmission among Swiss infants born to mothers with undetectable viral load and who did not receive neonatal PEP
24 February 2020. Related: Conference reports, HIV prevention and transmission.
17th European AIDS Conference (EACS 2019)
13 December 2019. Related: Conference reports.
Capsid inhibitor GS-6207 (lenacapavir): potential for 6 monthly dosing for MDR HIV
13 December 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir/lamivudine as dual ART
13 December 2019. Related: Conference reports, Antiretrovirals.
Weight changes with doravirine-based first line therapy
13 December 2019. Related: Conference reports, Antiretrovirals, Side effects.
Bone and renal changes in the ADVANCE trial
13 December 2019. Related: Conference reports.
10th International Workshop on HIV and Ageing
13 December 2019. Related: Conference reports, Ageing and life expectancy.
Impact of isolation and loneliness on older people living with HIV
13 December 2019. Related: Conference reports, Ageing and life expectancy.
17th European AIDS Conference (EACS 2019)
15 November 2019. Related: Conference reports.
EACS launch major update to European Treatment Guidelines (November 2019)
15 November 2019. Related: Conference reports, Guidelines.
Weight gain and metabolic syndrome with dolutegravir and TAF: results from the ADVANCE trial
15 November 2019. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
10th International Workshop on HIV and Ageing
15 November 2019. Related: Conference reports, Ageing and life expectancy.
Frailty in HIV care and the importance of lifestyle changes
15 November 2019. Related: Conference reports, Ageing and life expectancy.
Research into use of medicinal cannabis in HIV management
15 November 2019. Related: Conference reports, Ageing and life expectancy.
Vaping can help HIV positive smokers who are not motivated to quit cigarettes
15 November 2019. Related: Conference reports, Coinfections and complications, Cancer and HIV, Ageing and life expectancy.
IDWeek (2019), 2–6 October 2019, Washington DC
18 October 2019. Related: Conference reports.
HIV suppression and safety with ibalizumab at 48 weeks in expanded access
18 October 2019. Related: Conference reports, Antiretrovirals.
Oral cabotegravir and rilpivirine is durable for 5.5 years in LATTE study
18 October 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir plus rilpivirine had good virologic, safety record in clinics before single tablet available
18 October 2019. Related: Conference reports, Antiretrovirals.
Switching from TDF to TAF linked to higher BMI and cardio risk
18 October 2019. Related: Conference reports, Antiretrovirals, Side effects.